Tüdőrák: nyitott vizsgálatok itt: Peru
14 trials · From ClinicalTrials.gov, checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborozTrial-stage medicine
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Lima
- Age
- 18 év and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422EU 2023-506327-29-00Regiszter frissítve: 2026-11-09
3. fázisToborozTrial-stage medicine
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Arequipa, Cusco, Lima
- Age
- 18 év to 100 év
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356EU 2022-501863-41-00Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Where
- Arequipa, Lima, Surquillo
- Age
- 18 év and over
- People
- 614 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06170788EU 2023-503376-24-00Regiszter frissítve: 2026-11-03
2/3. fázisToborozTrial-stage medicine
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Arequipa, Cusco, Jesus Maria, Lima, Lima Cercado, Miraflores, San Isidro, Surquillo, Trujillo
- Age
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596EU 2023-508922-83-00Regiszter frissítve: 2026-10-30
3. fázisToborozTrial-stage medicine
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Where
- Chiclayo, Lima, Trujillo
- Age
- 18 év and over
- People
- 851 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06422143EU 2023-510128-66-00Regiszter frissítve: 2026-10-29
3. fázisToborozTrial-stage medicine
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- Lima
- Age
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738EU 2024-514281-39-00Regiszter frissítve: 2026-10-29
3. fázisToborozTrial-stage medicine
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Where
- Lima
- Age
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06627647EU 2024-515008-38-00Regiszter frissítve: 2026-10-28
1/2. fázisToborozTrial-stage medicine
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Where
- Lima
- Age
- 18 év and over
- People
- 152 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06996782EU 2024-519786-22-01Regiszter frissítve: 2026-10-28
3. fázisToborozTrial-stage medicine
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Lima
- Age
- 18 év and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729EU 2023-507776-42-00Regiszter frissítve: 2026-10-26
3. fázisToborozTrial-stage medicine
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- Lima
- Age
- 18 év and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248EU 2024-514500-14-00Regiszter frissítve: 2026-10-26
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Lima, San Borja
- Age
- 18 év and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510EU 2025-523586-18-00Regiszter frissítve: 2026-10-23
3. fázisToborozTrial-stage medicine
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Where
- Lima
- Age
- 18 év and over
- People
- 780 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312137EU 2023-508012-35-00Regiszter frissítve: 2026-10-15
3. fázisToborozTrial-stage medicine
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Where
- Lima Cercado, San Borja, San Isidro, Surquillo
- Age
- 18 év and over
- People
- 360 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07128199EU 2025-521775-31-00Regiszter frissítve: 2026-10-13
No phaseToborozResearch participation
Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
- Where
- Lima
- Age
- 18 év and over
- People
- 200 worldwide
- Run by
- Latin American Cooperative Oncology Group
See details and how to joinNCT07192991Regiszter frissítve: 2026-09-08
Minden vizsgálat (Tüdőrák) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.